Skip to main navigation
Skip to search
Skip to main content
MD Anderson Cancer Center Home
Help & FAQ
Home
Profiles
Research units
Equipment
Research output
Activities
Prizes
Search by expertise, name or affiliation
View Scopus Profile
Ping Li
Research Scientist
Thoracic Head & Neck Medical Oncology
https://orcid.org/0000-0002-0195-0871
h-index
4485
Citations
23
h-index
Calculated based on number of publications stored in Pure and citations from Scopus
2001
2025
Research activity per year
Overview
Fingerprint
Network
Research output
(42)
Similar Profiles
(6)
Fingerprint
Dive into the research topics where Ping Li is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Medicine and Dentistry
B-Cell Chronic Lymphocytic Leukemia
70%
Breast Cancer
63%
Leukemia Cell
63%
Cancer Cell
35%
Upregulation
22%
STAT3 Protein
21%
Neoplasm
18%
Metastatic Carcinoma
18%
Cell Signaling Pathway
15%
Cell Invasion
11%
Protein Synthesis
10%
Vasculotropin
10%
B Lymphocyte Receptor
10%
Phosphotransferase
9%
Tumor Cell
9%
Angiogenesis
8%
Ruxolitinib
8%
Mechanistic Target of Rapamycin
8%
Src Inhibitor
8%
Janus Kinase
7%
Endothelial Cell
7%
Gene Expression
7%
microRNA
7%
Synapsin II
7%
Neu Differentiation Factor
7%
Gelatinase B
7%
Chronic Myelogenous Leukemia
7%
T-Cell Response
7%
Hematopoietic Cell
7%
Carcinogenesis
7%
Tyrosine-Kinase Inhibitor
7%
Fatty Acid Metabolism
7%
Survivin
7%
Skin Fibroblast
7%
Epithelial Cell
7%
Oncogene C Myc
7%
Mesenchymal Stem Cell
7%
Lactate Dehydrogenase
7%
Ductal Carcinoma
7%
Glucose Metabolism
7%
Trastuzumab
7%
Pentraxin 3
7%
Intraductal Carcinoma
7%
Pentraxin
7%
Ibrutinib
7%
calcium activated,phospholipid dependent protein kinase
7%
Mesenchymal-Epithelial Transition
7%
Protein Kinase C Inhibitor
7%
Fatty Acid
7%
Gene Mutation
7%
Biochemistry, Genetics and Molecular Biology
STAT3
100%
Cancer Cell
40%
Upregulation
25%
Promoter Region
22%
Transcription
22%
MicroRNA
15%
Electrophoretic Mobility Shift Assay
15%
B-Cell Receptor
15%
Programmed Cell Death
14%
Transcription Factor
14%
Trastuzumab
14%
Cell Invasion
12%
Protein Biosynthesis
11%
Ruxolitinib
11%
Luciferase
11%
Immunoglobulin M
10%
Small Hairpin RNA
10%
Binding Site
10%
Serine
10%
Interleukin 6
10%
Mechanistic Target of Rapamycin
9%
Signal Transduction
9%
Janus Kinase
9%
Angiogenesis
8%
Small Interfering RNA
8%
CD5
8%
B Cell
8%
MiR-155
8%
T Cell
8%
Receptor Tyrosine Kinase-Like Orphan Receptor
7%
Protein Kinase B
7%
Gene Expression
7%
Pentraxin
7%
Oncogene
7%
Immunoprecipitation
7%
Chromatin Immunoprecipitation
7%
Phosphotransferase
7%
Kinase
7%
Transfection
7%
Diacylglycerol Lipase
7%
Cell Adhesion
7%
Cancer Growth Factor
7%
Tumor Suppressor Protein
7%
CD36
7%
Fatty Acid Transport
7%
PTX3
7%
Chondrocyte
7%
Gelatinase B
7%
Casein Kinase
7%
MMP9
7%
Keyphrases
Chronic Lymphocytic Leukemia Cells
90%
Chronic Lymphocytic Leukemia
50%
ErbB2
32%
Signal Transducer and Activator of Transcription 3
30%
Trastuzumab
15%
Phosphorylation
14%
Gli1
14%
Trastuzumab Resistance
14%
Free Fatty Acid Oxidation
14%
Pentraxin 3 (PTX3)
14%
Tumor Microenvironment
14%
Vascular Endothelial Growth Factor
10%
Trastuzumab-resistant
10%
Lipoprotein Lipase
9%
B Cell Receptor
9%
Breast Cancer
9%
Metastatic Breast Cancer
8%
Ruxolitinib
8%
Induced Apoptosis
8%
Protein Synthesis
8%
Chromatin Immunoprecipitation (ChIP)
8%
Constitutively Active
8%
Novel Mechanism
8%
Src Activation
8%
Transcription Factor
8%
Src Inhibition
8%
Myelofibrosis
7%
Survival Benefit
7%
Angiogenesis
7%
Breast Cancer Invasion
7%
Overexpression
7%
Receptor Tyrosine Kinase-like Orphan Receptor 1
7%
Small Interfering RNA (siRNA)
7%
Metastasis
7%
Cluster of Differentiation 36 (CD36)
7%
Interferon Regulatory Factor 4 (IRF4)
7%
Combination Treatment
7%
Lysine
7%
Tumor Cells
7%
Immune Cells
7%
Caspase-3
7%
Src Inhibitor
7%
P-STAT3
7%
T Cell Response
7%
Single Group
7%
Phase II Trial
7%
Spontaneous Metastasis
7%
Tumor Inhibition
7%
Invasive Breast Cancer
7%
C-Myc
7%
